BridgeBio Pharma (BBIO) Amortizatization of Intangibles (2018 - 2026)

BridgeBio Pharma has disclosed Amortizatization of Intangibles across 9 years of filings, most recently posting $1.5 million for Q1 2026.

• Amortizatization of Intangibles for Q1 2026 came in at $1.5 million, up 47.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.4 million (up 73.97% YoY), and the FY2025 annual result was $4.9 million, up 19.27% from the prior year.
• Amortizatization of Intangibles came in at $1.5 million for Q1 2026 at BridgeBio Pharma, roughly flat from $1.5 million in the prior quarter.
• In the past five years, Amortizatization of Intangibles ranged from a high of $52.1 million in Q2 2025 to a low of -$49.7 million in Q3 2025.
• The 5-year median for Amortizatization of Intangibles is $1.9 million (2022), against an average of $1.4 million.
• Peak annual rise in Amortizatization of Intangibles reached 3024.22% in 2025, while the deepest fall reached 8705.5% in 2025.
• BridgeBio Pharma's Amortizatization of Intangibles stood at $2.1 million in 2022, then tumbled by 228.13% to -$2.7 million in 2023, then soared by 136.81% to $991000.0 in 2024, then surged by 47.23% to $1.5 million in 2025, then advanced by 0.48% to $1.5 million in 2026.
• The last three Amortizatization of Intangibles figures came in at $1.5 million (Q1 2026), $1.5 million (Q4 2025), and -$49.7 million (Q3 2025), per Business Quant data.